Quality of life in pediatric patients before and after cosmetic camouflage of visible skin conditions - 16/10/14
, Sandra Ondrejchak, RN a, Roxanne Gendron, BSc a, Afshin Hatami, MD a, Catherine C. McCuaig, MD a, Julie Powell, MD a, Danielle Marcoux, MD aAbstract |
Background |
Visible vascular and pigmentary conditions have a negative impact on children's and adolescents' quality of life (QoL). We sought to quantitate the effect of visible skin anomalies and their camouflage on QoL.
Methods |
In all, 41 patients, 5 years of age and older, were taught to use cosmetic camouflage. QoL was assessed using the Children's Dermatology Life Quality Index (CDLQI) before and 6 months after the intervention. Satisfaction and use were evaluated after 1 and 6 months.
Results |
Baseline QoL scores revealed a small impact of vascular anomalies (CDLQI score 4.2) and a small to moderate effect of pigmentary anomalies (CDLQI score 6.1). Six months after the intervention, QoL improved in the study population as a whole (CDLQI score 5.1 vs 2.1, P < .001), with significant improvements documented for facial lesions and vascular malformations. Cosmetic camouflage was well tolerated and patients with pigmentary anomalies were more likely to continue using the products.
Limitations |
Limitations include small study population, few male patients, cultural influences not addressed, and limited range of conditions.
Conclusions |
Children and teenagers with visible vascular and pigmentary anomalies experience an impairment of QoL that is abrogated by introduction to use of cosmetic camouflage.
Le texte complet de cet article est disponible en PDF.Key words : camouflage make-up, Children's Dermatology Life Quality Index, cosmetic camouflage, nevi, postinflammatory dyspigmentation, quality of life, telangiectasia, vascular malformations, vitiligo
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
Vol 71 - N° 5
P. 935-940 - novembre 2014 Retour au numéro
Article précédent
- Syringotropic mycosis fungoides: Clinical and histologic features, response to treatment, and outcome in 19 patients
- Adèle de Masson, Maxime Battistella, Marie-Dominique Vignon-Pennamen, Bénédicte Cavelier-Balloy, Frédéric Mouly, Michel Rybojad, Jean-David Bouaziz, Antoine Petit, Anne Saussine, Sophie Ronceray, François Le Gall, Caroline Ram-Wolff, Philippe Assouly, Olivier Dereure, Pascal Joly, Alexiane Dallot, Alain Dupuy, Céleste Lebbé, Isabelle Moulonguet, Jacqueline Rivet, Anne Janin, Martine Bagot
- Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine
- Mark G. Kirchhof, Monica A. Miliszewski, Sheena Sikora, Anthony Papp, Jan P. Dutz
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?